AuthorisedTherapeutic exploratory (Phase II)Interventional

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

This research, called LIMPID, is a Phase II study exploring new treatments for advanced non-small cell lung cancer (a common type) in patients who also have a lung condition known as Interstitial Lung Disease (ILD). Researchers are testing different medicines, both as initial treatment and if the first treatment isn't enough. The main goals are to see how many patients' cancer stabilises or shrinks, and to monitor for any breathing difficulties caused by the treatments, especially within the first six months. The study also investigates how long people live, how long their cancer stays controlled, and their overall quality of life, to find safer and more effective ways to manage both conditions.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Intergroupe Francophone De Cancerologie Thoracique

Enrolment target

108

Start

17 Apr 2026

Non Small Cell Lung Cancer, Interstitial Lung Disease

What is this study about?

This study is called LIMPID, and it's a 'Phase II' clinical trial. This means it's a more advanced stage of research, building on earlier studies to see if new treatments are promising for a wider group of people. The main focus is on patients who have a type of advanced lung cancer called 'Non-Small Cell Lung Cancer' (NSCLC) and also have another lung condition called 'Interstitial Lung Disease' (ILD).

Interstitial Lung Disease makes the lungs scarred and stiff, which can cause breathing problems. Treating lung cancer in people who already have ILD can be tricky because some cancer treatments might make the ILD worse. This study aims to find the best and safest ways to treat lung cancer in these patients, both as a first treatment and if that first treatment doesn't work as well as hoped.

The researchers will be looking at several things. For patients receiving treatment for the first time, they'll check how many patients see their cancer shrink or stay stable after 8 weeks. For those receiving a second type of treatment, a key focus will be on whether the treatment causes any new or worsened breathing problems that might lead them to stop treatment in the first 6 months. They will also look at how long people live, how long the cancer is kept under control, and how treatments affect their overall well-being. This will help doctors understand which treatments are most effective and safest for this specific group of patients.

Key takeaways

Study focuses on advanced lung cancer (NSCLC) AND a lung condition (ILD).
Aims to find safer, more effective treatments for these complex cases.
Compares different medications as first or second-line treatment.
Closely monitors cancer response and potential breathing problems.
Also evaluates quality of life and side effects.
Open to adults aged 18 and over, both men and women.

Who may be eligible?

To be considered for this study, you would need to be an adult aged 18 or over. This study is open to both men and women.

Key medical requirements would involve having been diagnosed with advanced non-small cell lung cancer (a type of lung cancer) and also having Interstitial Lung Disease, which is a condition that affects the lungs. The study team will review all your medical information carefully to make sure the study is right for you and that you meet all the necessary health criteria.

It's important to remember that participating in a clinical trial is a big decision, and the study doctors will discuss all the details with you to ensure it's a suitable option for your unique situation.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with advanced Non-Small Cell Lung Cancer?
Do you also have a condition called Interstitial Lung Disease?
Are you able to attend regular hospital visits for treatment and check-ups?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you would receive one of the study treatments in either the first line (initial treatment) or second line (if the first treatment isn't fully effective) setting. You would have regular appointments, likely including scans such as CT scans, to check how your cancer is responding and to monitor for any changes in your lung condition. These scans would typically happen around 8 weeks into the treatment and at other regular intervals. You would also have blood tests and physical examinations to keep track of your general health and how you're tolerating the treatment.

The research team will also assess your quality of life using questionnaires, like the FACT-L, to understand how you are feeling generally. They will closely watch for any side effects, particularly any new or worsening breathing problems. The total duration of your participation would depend on how your treatment progresses and whether you continue to benefit, but important assessments are made within the first 6 months.

Potential risks and benefits

Participating in any clinical trial involves potential benefits and potential risks. A potential benefit of this study is receiving an active treatment that may help control your lung cancer and potentially improve your quality of life, with close monitoring by a specialist team. There's also the chance that the treatment might not work for you, or it could cause side effects. Given that you also have Interstitial Lung Disease, a specific risk being closely watched is that the treatments might worsen your breathing. The research team will carefully monitor you for any side effects and manage them appropriately. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is Non-Small Cell Lung Cancer?

It's the most common type of lung cancer, and 'advanced' means it has spread or is difficult to treat with surgery alone.

What is Interstitial Lung Disease (ILD)?

ILD is a group of conditions that cause scarring and stiffness in the lungs, making it harder to breathe.

What does 'Phase II' mean for a clinical trial?

It means the study is looking at whether a new treatment is effective and safe in a larger group of people, after earlier studies showed promise.

What kind of treatments are being studied?

The study is looking at several different medications, some of which are already used for cancer, in new combinations or settings for people with ILD.

Will I know which treatment I'm receiving?

The study team will explain the specific treatment plan to you before you agree to participate.